Before deciding the "societal value" of the new medicine, its performance in clinical trials, possible side effects, and accessibility must be closely examined.
Lecanemab is the first drug proven to slow the progression of Alzheimer's. Its manufacturer Eisai calculated its societal value to determine a suitable price.
